[의학신문·일간보사=김영주 기자]Korea’s 30th new drug, K-Cap, is aiming for China, the world’s No. 1 peptic ulcer drug market.
HK inno.N announced on the 3rd that its Chinese partner Luoxin held an event to commemorate the large-scale launch of its new gastroesophageal reflux disease K-cap tablet (ingredient name: tegoprazan) on the 28th of last month and started full-scale local sales.
This is only 15 days following receiving the product approval from the National Drug Administration (NMPA) of China on the 13th of last month, and the K-cap will be released under the local name ‘Taishinzan (泰欣赞)’, which means ‘helping with great pleasure’.
Thousands of executives and employees, including key company executives, participated in the event online and offline, promising the success of Taishin Tsang.
In particular, Luoxin set an annual sales target of 1 billion yuan (regarding 200 billion won) for next year, the second year of its launch, and plans to foster it as a representative blockbuster product with annual sales of 3 billion yuan (regarding 600 billion won) in the mid- to long-term. said the plan.
In close partnership with HK Innoen, Luoxin is steadily expanding the indications for Taixin salty, while expanding the dosage form to future injections following the existing tablets, ultimately aiming to become the No.
As K-caps are launched in China, HK Innoen’s global K-caps sales are expected to expand in earnest due to the generation of technology fees and royalties for each stage.
“We have high expectations for Taixin Salt to the extent that we have focused on accelerating the timeline, which normally takes several months following approval for product approval, from product launch to product launch,” said Luo Xin, CEO of Liu. said.
HK Innoen CEO Kwak Dal-won said, “We plan to actively support Luoxin so that K-Cap can become a blockbuster drug in China. ” he said.
So far, a total of 27 countries have signed contracts for exporting technology and finished products to Kcap, and the number of countries entering overseas markets is expected to increase rapidly in the future, as it is still in discussions with candidate partners in Europe and the Middle East.
